DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis Drug Pipeline Capsule - 2012 Update" report to their offering.
Fore Pharma's latest report 'Global Idiopathic Pulmonary Fibrosis Drug Pipeline Capsule - 2012 Update' provides most up-to-date information on key Research and Development activities (R&D) in the global Idiopathic Pulmonary Fibrosis market. It covers active Idiopathic Pulmonary Fibrosis pipeline molecules in various stages of clinical trials, preclinical research, and drug discovery.
This report helps executives track competitors pipeline molecules. The information presented in this report can be used for identifying partners, evaluating opportunities, formulating business development strategies, executing in-licensing and out-licensing deals.
The report provides information on pipeline molecules by company and mechanism of action across the R&D stages. It also provides information on pipeline molecules developed in leading geographies (North America and Europe). Licensing activities are thoroughly captured in this report.
Key Topics Covered:
1. Idiopathic Pulmonary Fibrosis - Disease Overview
2. Idiopathic Pulmonary Fibrosis Pipeline Overview
3. Idiopathic Pulmonary Fibrosis Phase 3 Clinical Trial Pipeline Insights
4. Idiopathic Pulmonary Fibrosis Phase 2 Clinical Trial Pipeline Insights
5. Idiopathic Pulmonary Fibrosis Phase 1 Clinical Trial Pipeline Insights
6. Idiopathic Pulmonary Fibrosis Preclinical Research Pipeline Insights
7. Idiopathic Pulmonary Fibrosis Discovery Stage Pipeline Insights
8. Idiopathic Pulmonary Fibrosis Drug Development Activities - Geographic Landscape
8.1. Idiopathic Pulmonary Fibrosis R&D Activities in North America
8.2. Idiopathic Pulmonary Fibrosis R&D Activities in Europe
9. Idiopathic Pulmonary Fibrosis Pipeline - Licensing Activities
Table 1. Idiopathic Pulmonary Fibrosis Pipeline Molecules - Phase 3 Clinical Trial
Table 2. Idiopathic Pulmonary Fibrosis Pipeline Molecules - Phase 2 Clinical Trial
Table 3. Idiopathic Pulmonary Fibrosis Pipeline Molecules - Phase 1 Clinical Trial
Table 4. Idiopathic Pulmonary Fibrosis Pipeline Molecules - Preclinical Research
Table 5. Idiopathic Pulmonary Fibrosis Pipeline Molecules - Drug Discovery
Table 6. Idiopathic Pulmonary Fibrosis R&D Activities by Geography
Table 7. Idiopathic Pulmonary Fibrosis Pipeline Molecules - North America
Table 8. Idiopathic Pulmonary Fibrosis Pipeline Molecules - Europe
Table 9. Idiopathic Pulmonary Fibrosis Pipeline - Licensing Activities
Figure 1. Idiopathic Pulmonary Fibrosis Pipeline Molecules by R&D Stage
Figure 2. Idiopathic Pulmonary Fibrosis R&D Activities by Geography
For more information visit http://www.researchandmarkets.com/research/w3585t/global_idiopathic